‘AutoImmunoprofiler’ Builds on Success in Cancer Research to Advance Treatments for Autoimmune Diseases

By Alan Toth on February 22, 2021
UCSF Partners With Eli Lilly to Better Understand Underlying Drivers of Autoimmunity and Accelerate the Development of Better Therapies.  MORE

Calico and AbbVie Take UCSF Technology Into Clinical Trials

February 03, 2021
Calico Life Sciences and AbbVie announced clinical-stage programs in two areas – immuno-oncology and neurodegeneration, currently in Phase I studies. The lead Calico neurodegeneration molecule is based on novel technology licensed from the lab of Peter Walter, Professor of Biochemistry and...

Sana Biotechnology Files for IPO

By Megan Campbell on January 20, 2021
UCSF start up Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. The preclinical biotech is looking to raise up to $150 million on the Nasdaq under the symbol SANA. MORE

'Invisible' stem cells evade natural killer cells using immune 'off-switch'

January 08, 2021
UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer...

Alliance Management an Integral Part of Successful Industry Engagement

By David Schwartz on January 05, 2021
Convincing a potential industry partner that an initial collaboration is attractive is one thing; keeping that partner on board and strengthening that relationship as the years go on is quite another, and that’s where alliance management comes in. Peter Kotsonis, UCSF's Strategic Alliances...

UCSF and BridgeBio Pharma to Accelerate Therapies for Genetic Diseases

By Nicholas Weiler on December 22, 2020
SAN FRANCISCO – December 23, 2020 - UC San Francisco and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovations in genetically driven diseases into potential therapeutics for patients.

Autobahn Collaboration to Accelerate UCSF Innovation from Bench to Bedside

By Nicholas Weiler on December 18, 2020
Partnership with Autobahn Labs Aims to Pave Road Through ‘Valley of Death’ Faced by Novel Therapies

UCSF Startup Siolta and Bio-Me to Collaborate

November 24, 2020
Bio-Me and UCSF startup Siolta Therapeutics, founded by Professor Susan Lynch, aim to develop and market predictive test for infants to determine microbiome-based pediatric allergies and asthma. More

Epygenix Therapeutics Announces Phase 2 of Zebrafish Study

October 14, 2020
Epygenix Therapeutics, Inc., a privately-held biopharmaceutical company developing precision medicine for Dravet Syndrome, announced today that the first patient has been enrolled in a Phase 2, 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Trial of EPX-100 as...

PrinterPrezz Receives Clearance for 3D Printed Spine Devices Based on UCSF Technology

By Teresa J. Thuruthiyil on October 13, 2020
PrinterPrezz, Inc., a medical polymer and metal 3D printing, nanotechnologies and implant design company, today announced the U.S. Food and Drug Administration (FDA) clearance of the company’s 510(k) for the PrinterPrezz GAIA™ Lumbar Interbody Fusion Device (LIFD) family of spine implants as a...